Press release
Global Nonalcoholic Steatohepatitis Treatment (Phase III Drugs) Market USD 19.8 Billion by 2025
Visit the Nonalcoholic Steatohepatitis Treatment Market – Phase III Drugs In Pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) 2016-2025 report at https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use. Nonalcoholic fatty liver disease (NAFLD) gradually is recognized as a common reason of chronic liver disease. NAFLD spans a spectrum of clinicopathologic entities from simple hepatic steatosis to nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Nearly 10% to 20% of the general population affected by NAFLD suffers from NASH. Therefore, the diagnosis methods for NAFLD helps in the prediction of NASH occurrence. The diagnosis methods include evaluation of liver enzymes, hepatic imaging and liver biopsy.
The global nonalcoholic steatohepatitis treatment (Phase III Drugs) market report provides market size (Revenue USD Million 2015 to 2025), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2025).
The global nonalcoholic steatohepatitis treatment (Phase III Drugs) market segmentation is based on phase III drugs in pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor).
The global nonalcoholic steatohepatitis treatment (Phase III Drugs) market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global nonalcoholic steatohepatitis treatment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global nonalcoholic steatohepatitis treatment market and included in this report are Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., GENFIT SA, and Zydus Cadila.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/
Health Care Market Research Analytics Services
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 736-9294.
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Nonalcoholic Steatohepatitis Treatment (Phase III Drugs) Market USD 19.8 Billion by 2025 here
News-ID: 389371 • Views: …
More Releases from iHealthcareAnalyst, Inc.
Global Amyotrophic Lateral Sclerosis Devices Market $19.5 Billion by 2029
The global market for amyotrophic lateral sclerosis devices or motor neuron disease devices anticipated to reach $19.5 billion by 2029, growing at a CAGR of 7.3% over the forecast period, driven by increasing incidence, rising geriatric population, lack of curative treatment, growing public awareness, and technological advancements in palliative care.
https://www.ihealthcareanalyst.com/global-amyotrophic-lateral-sclerosis-devices-market/
Amyotrophic lateral sclerosis or Lou Gehrig's disease or motor neuron disease (MND) is characterized by progressive degeneration of the motor nerve…
Global Blood Gas Monitoring Products Market Growing at CAGR of 6.2% to Reach $5. …
The global market for blood gas monitoring products is estimated to reach $5.5 billion by the end of 2025, expanding at a CAGR of 6.2% during the forecast period, supported by growing geriatric population, rising prevalence of chronic diseases, and technological advances.
The global blood gas monitoring devices market research report provides market size (Revenue US$ Million 2017 to 2025), market share analysis, growth trends and forecast (CAGR%, 2019 to 2025).…
Advances in Mobile Connectivity Services to Drive Telemedicine Technologies and …
According to a new market research report Telemedicine Technologies and Services Market 2015-2023 published by iHealthcareAnalyst, Inc., the global computer-aided detection market to reach US$ 73.2 Billion by 2023, expanding at a CAGR of 13.5% from 2018-2023.
Visit the Global Telemedicine Technologies and Services Market Analysis and Forecast 2018-2023 report at https://www.ihealthcareanalyst.com/report/telemedicine-technologies-services-market/
The global telemedicine technologies and services market newly published (updated 2018) report estimates the market size (US$ million 2015-2023)…
Global Internet Pharmacies Market to Cross US$ 100 Billion by 2023
The global internet pharmacies market is estimated to reach US$ 106 Billion by 2023, growing at a CAGR of 15.7% over the forecast period, driven by rising personal disposable income, lower prices, surge in internet penetration, stupendous growth of online retail market and a large number of online players entering the online healthcare product segment.
The major players are in a race to increase their share in the industry by…
More Releases for III
Ytterbium(III) Sulfate Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ytterbium(III) Sulfate Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
Ytterbium(III) Sulfate Market Size And Scope
The Ytterbium(III) Sulfate market is projected to grow significantly, with a market size valued at approximately USD 110.3 million in…
Iron(III) Isopropoxide Market 2024 Research Report
Iron(III) Isopropoxide Market
The global Iron(III) Isopropoxide market was valued at US$ 62 million in 2023 and is anticipated to reach US$ 99 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
View Sample Report
https://reports.valuates.com/request/sample/QYRE-Auto-10Y12819/Global_Iron_III_Isopropoxide_Industry_Research_Report_Growth_Trends_and_Competitive_Analysis_2022_2028
Report Scope
The Iron(III) Isopropoxide market size, estimations, and forecasts are provided in terms of output/shipments (Gram) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the…
What is Ruthenium III Chloride used for?
Ruthenium(III) chloride hydrate, also known as ruthenium trichloride hydrate, is a compound of great significance in various fields. This compound consists of ruthenium, chlorine and water molecules. With its unique properties, ruthenium(III) chloride hydrate has a wide range of applications in different industries. In this article, we explore the uses of ruthenium(III) chloride and emphasize its importance.
Ruthenium(III) chloride hydrate is widely used as a catalyst in organic synthesis. It can…
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipelin …
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed speech and behaviour problems.
Download the sample report @ https://www.pharmaproff.com/request-sample/1146
In later stages of this disorder, people…
Global Antithrombin III Deficiency Testing Market
The Antithrombin III Deficiency Testing Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Antithrombin deficiencies are mainly divided into two types: type I and type II. The type I antithrombin deficiency is characterized by an inadequate amount of normal antithrombin present in…
EXCEEMO Industrial SATA III SSD
Extremely impressive performance, the highest reliability and guaranteed fixed BOM - all in one service package for industrial customers
EXCEEMO, the memory and storage specialist from Landsberg am Lech, presents the industrial 2.5“ SATA III Solid-State-Drives with ultra-fast read/write transfer speed of up to 555MB/515MB per second and proven long-term reliability. The noiseless, energy-efficient and particularly robust solid state drives are available both in standard grade (0°/+70°C-MLC/SLC) and in industrial…
